CRISPR Therapeutics (NASDAQ:CRSP) released its quarterly earnings data on Thursday. The company reported $9.44 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $3.52 by $5.92, MarketWatch Earnings reports. CRISPR Therapeutics had a negative return on equity of 27.42% and a negative net margin of 35,630.97%.
Shares of NASDAQ CRSP traded up $2.22 during midday trading on Friday, hitting $121.22. The stock had a trading volume of 52,287 shares, compared to its average volume of 1,786,531. The company has a market cap of $9.18 billion, a P/E ratio of -21.14 and a beta of 2.28. CRISPR Therapeutics has a 1-year low of $76.71 and a 1-year high of $220.20. The business has a fifty day moving average of $129.19.
In other news, President Rodger Novak sold 25,000 shares of CRISPR Therapeutics stock in a transaction dated Monday, June 21st. The stock was sold at an average price of $128.62, for a total value of $3,215,500.00. Following the transaction, the president now directly owns 646,836 shares of the company's stock, valued at approximately $83,196,046.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bradley J. Phd Bolzon sold 10,000 shares of CRISPR Therapeutics stock in a transaction dated Friday, June 11th. The shares were sold at an average price of $126.61, for a total value of $1,266,100.00. Following the completion of the transaction, the director now directly owns 24,948 shares in the company, valued at $3,158,666.28. The disclosure for this sale can be found here. Insiders sold a total of 120,375 shares of company stock worth $16,770,580 over the last ninety days. Corporate insiders own 17.10% of the company's stock.
Several research firms have issued reports on CRSP. Citigroup upgraded CRISPR Therapeutics from a "sell" rating to a "neutral" rating and increased their price objective for the stock from $55.00 to $132.00 in a research report on Monday, June 14th. Jefferies Financial Group upgraded CRISPR Therapeutics from a "hold" rating to a "buy" rating and set a $172.00 price objective for the company in a research report on Wednesday, April 21st. Chardan Capital cut their price objective on CRISPR Therapeutics from $175.00 to $171.00 and set a "buy" rating for the company in a research report on Friday. Barclays raised their price target on CRISPR Therapeutics from $140.00 to $160.00 and gave the company an "overweight" rating in a research report on Wednesday, April 21st. Finally, Evercore ISI upgraded CRISPR Therapeutics to an "outperform" rating in a research report on Thursday, May 13th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and twelve have assigned a buy rating to the company. The company presently has an average rating of "Buy" and an average price target of $159.50.
About CRISPR Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.
See Also: Blockchain
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.